APGE compared with ANL: revenue, margins and what each company keeps, and the suppliers and customers both name

APGEApogee Therapeutics, Inc.

Mkt capRevenueRevenue

ANLAdlai Nortye Ltd.

Mkt capRevenueRevenue

Compare

APGEApogee Therapeutics, Inc.

ANLAdlai Nortye Ltd.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

APGE

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±0.6%▼−0.14%×0.17

Q1 FY26±7.8%▲+1.89%×0.24

Q3 FY25±8.7%▲+3.77%×0.44

Aug 11 '25±7.7%▼−2.09%×0.27

ANL

No earnings history for ANL.

= impliedAPGE realized, solidANL realized, hatchedOne scale, both sides: full bar = 9%× = |realized| ÷ impliedSource: market data

APGEApogee Therapeutics, Inc.

135.07· pre 135.10· delayed

Mkt cap$10.2B

ANLAdlai Nortye Ltd.

9.41· pre 9.41· delayed

Pre-marketNov 2 '26delayed

Mkt cap$916.1M

Compare

Pre-marketNov 2 '26delayed

APGEApogee Therapeutics, Inc.

ANLAdlai Nortye Ltd.

135.07pre 135.10delayed

Price

9.41pre 9.41delayed

$10.2B

Mkt cap

$916.1M

APGE135.07vsANL9.41Pre-marketNov 2 '26delayed